Abstract
Background In areas highly endemic for malaria, Plasmodium falciparum (Pf) infection prevalence peaks in school-age children, adversely affecting their health and education. School-based intermittent preventive treatment reduces this burden, however concerns about cost and widespread use of antimalarial drugs have limited enthusiasm for this approach. School-based screening-and-treatment is an attractive alternative. We conducted a school-based cohort study to evaluate the impact of screening-and-treatment on the prevalence of Pf infection and anemia in two different transmission settings.
Methods We screened 704 students in four Malawian primary schools for Pf infection using rapid diagnostic tests (RDTs). Those testing positive were treated with artemether-lumefantrine. Outcomes were Pf infections detected by microscopy or PCR and anemia after six weeks.
Results Prevalence of infection by RDT at screening was 37% (range among schools 9-64%). We detected a significant reduction after six weeks in infections by microscopy (adjusted relative reduction (aRR) 47.1%, p<0.0001) and PCR (aRR 23.1%, p<0.0001), but no reduction in anemia. In low, seasonal prevalence areas, sub-patent infections at screening led to persistent infection, but not disease, during follow-up. In high transmission settings, new infections frequently occurred within six weeks after treatment.
Conclusions School-based screening-and-treatment reduced Pf infection but not anemia. This approach could be enhanced in low transmission settings by using more sensitive screening tests and in high transmission settings by repeating the intervention or using longer acting drugs.
Summary Malaria screening-and-treatment reduced P. falciparum infections but not anemia. Because rapid diagnostic tests failed to detect low-density infections, screening tests with higher sensitivity may be needed in low transmission areas where low-density infections make-up a larger proportion of infections.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04858087
Funding Statement
This work was supported by the U.S. National Institutes of Health [U19AI089683, K24AI114996 to M.K.L., and K23AI135076 to L.M.C], the Thrasher Research Fund Early Career Award [to L.M.C], and the Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases [to L.M.C.]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Malawi College of Medicine Research and Ethics Committee and the Institutional Review Board of the University of Maryland Baltimore
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
After publication, data will be made available through publicly available databases.
